美国证券交易所 (AMEX) · 生物技术 · USD
NanoViricides, Inc. (NNVC) 股票分析
NanoViricides, Inc.（NNVC）是在美国证券交易所 (AMEX)上市的生物技术股票，以美元交易。
最后更新: 2026年10月21日
价格走势
暂无价格数据
悬停查看每日收盘价。虚线表示区间起始价。
NNVC 关键统计数据
数据截至2026年10月21日交易
- 开盘价
- $1.47
- 前收盘价
- $1.48
- 当日波动区间
- 1.42–1.52
- 52周波动区间
- 0.85–2.23
- 成交量
- 20.60万
- Beta系数股价相对大盘的波动幅度。1.0与大盘同步，高于1.0波动更大，低于1.0更小。
- 1.79
估值
- 市值
- $3854.27万
- 市盈率
- 亏损
- 每股收益（近12个月）过去十二个月归属于每股的利润。
- −0.41
财务（财年）
- 营业收入（财年）
- $0.00
- 净利润（财年）
- −$946.70万
- 流通股数
- 2552.50万
- 一年回报率
- +2.03%
股息与日期
- 平均成交量
- 41.56万
仅显示公司披露的指标。 数据由Yahoo Finance通过yfinance提供。每日更新。
关键数据
截至2026年10月21日，NNVC收盘价为$1.51，1年回报率为+2.03%。
NanoViricides, Inc.（NNVC）的市值为$3854.27万。
2025财年，NNVC的营业收入为$0.00。
NNVC 历年回报率
NanoViricides, Inc.（NNVC）10年回报：$10,000变成了多少
- 1年
- $10,000 $10,203
- +2.03%
- 5年
- $10,000 $2,967
- −70.33%
- 10年
- $10,000 $503
- −94.97%
如果在10年前，即2016年10月21日收盘时，向NanoViricides, Inc.（NNVC）投资$10,000，按2026年10月21日收盘价计算将变为$503：累计−94.97%，年化−25.84%。基于经拆股和股息调整的收盘价进行的历史测算，未计入费用和税费。
历年回报率根据每日收盘价计算。 不完整年度以浅色显示并标有星号。
−77.27%+40.20%+33.63%
2016*2017201820192020202120222023202420252026*
| 年份 | 回报率 |
|---|---|
| 2026 (不完整年度) | +33.63% |
| 2025 | −20.98% |
| 2024 | +40.20% |
| 2023 | −8.11% |
| 2022 | −70.16% |
| 2021 | +29.62% |
| 2020 | +14.34% |
| 2019 | −37.25% |
| 2018 | −77.27% |
| 2017 | −17.76% |
| 2016 (不完整年度) | −36.69% |
数据截至2026年10月21日。
NNVC 各财年营收与利润
财年截至六月营业收入净利润
2022202320242025
| 财年 | 营业收入 | 净利润 | 净利率 |
|---|---|---|---|
| 2025 | $0.00 | −$946.70万 | — |
| 2024 | $0.00 | −$829.41万 | — |
| 2023 | $0.00 | −$858.86万 | — |
| 2022 | $0.00 | −$810.69万 | — |
| 财年 | 营业收入 | 毛利 | 营业利润 | 净利润 | 净利率 |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$959.16万 | −$946.70万 | — |
| 2024 | $0.00 | — | −$851.61万 | −$829.41万 | — |
| 2023 | $0.00 | — | −$894.35万 | −$858.86万 | — |
| 2022 | $0.00 | — | −$811.36万 | −$810.69万 | — |
为公司报告货币口径的年度公布数据。 数据截至2025年6月30日。
最新新闻
NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials
YahooPhase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides
YahooNanoViricides Says Its Phase IIA Ebola Treatment Clinical Trial Of NV-387 Oral Gummies Is Progressing Well
BenzingaNanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026
YahooNanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
YahooNanoViricides Updates Phase II Trial Of NV-387 Oral Gummies For Ebola Treatment In DRC; Reports Cautious Early Enrollment
Benzinga
全部18篇文章 ↓收起 ↑
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials
YahooNanoviricides Q4 EPS $(0.10), Inline
BenzingaClinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides
YahooPhase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides
YahooClinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in DR Congo with 48% Crude Fatality Rate, Says NanoViricides
YahooNanoViricides Announces That Its Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In Democratic Republic Of Congo Is Scheduled To Begin Next Week
BenzingaNanoViricides Says Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus And Other Ebola Viruses In DR Congo Registered In Pan African Clinical Trials Registry Database
BenzingaWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
YahooNanoViricides Advances NV-387 Measles Treatment Toward Phase II Trials Following FDA Rare Pediatric Disease Designation
BenzingaNanoViricides Announces Expects Its Phase II Clinical Trial Of NV-387 Oral Gummies To Treat Bundibugyo Ebolavirus And Other Ebola Viruses To Begin Soon In The Democratic Republic Of Congo
BenzingaNanoViricides Wins DRC Approval To Begin Phase II Trial Of NV-387 Oral Gummies For Ebola
BenzingaNanoViricides Awaits Regulatory Approval To Begin Phase II Clinical Trial Of NV-387 Oral Gummies As Treatment For Current Bundibugyo Ebolavirus In Democratic Republic Of Congo
Benzinga
新闻由第三方来源提供。不构成投资建议。
分析
数据生成以上所有数字均在每日重新生成时从本页自身的数据中读取。仅供参考，不构成投资建议。 数据截至2026年10月21日。
相关生物技术股票
VRTX
查看所有生物技术股票 →
Vertex Pharmaceuticals Incorporated
$1329.45亿
MRNAModerna, Inc.
$981.36亿
REGNRegeneron Pharmaceuticals, Inc.
$829.48亿
ARGXargenx SE
$559.72亿
ONCBeOne Medicines AG
$439.67亿
RVMDRevolution Medicines, Inc.
$416.41亿
医疗保健热门股票
LLY
查看所有医疗保健股票 →
Eli Lilly and Company
$1.13万亿
JNJJohnson & Johnson
$6212.24亿
ABBVAbbVie Inc.
$5032.75亿
UNHUnitedHealth Group Incorporated
$3742.97亿
MRKMerck & Co., Inc.
$3697.80亿